Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the third quarter 2011. Onyx reported a non-GAAP net loss of $19.5 million, or $0.31 per diluted share, for the third quarter 2011 compared to a non-GAAP net income of $55.3 million, or $0.84 per diluted share, for the same period in 2010. A description of the non-GAAP calculations is provided below in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

"We are continuing our strong momentum in 2011, building two robust oncology platforms – one in kinase inhibition and the other in proteasome inhibition," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The submission of our new drug application for carfilzomib demonstrates our commitment to getting this important therapy to patients as quickly as possible. For the kinase inhibitor business, Nexavar delivered another quarter of solid operating performance, primarily driven by sales growth in the Asia Pacific and U.S. regions, and we continue to see even more opportunity with this therapy in the approved indications and, potentially, other tumor types. The recent Bayer settlement also gives us a significant interest in regorafenib, and with a successful pivotal trial in colorectal cancer, we are excited about the prospect of this new therapy for patients."

Recent business highlights include submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during September 2011 under the accelerated approval process for carfilzomib, and the restructuring of our partnership with Bayer HealthCare Pharmaceuticals Inc., or Bayer, during October 2011 for the global development and marketing of Nexavar® (sorafenib) tablets. The Company also entered into a new agreement with Bayer related
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... Inc.,(Nasdaq: OMCL ), a leading provider of system ... third quarter ended September,30, 2007. GAAP results: Revenues ... $3.3 million or 6.4% from second quarter 2007 revenue ... the third quarter of 2006. Third quarter 2007 ...
... the cystic fibrosis chain uncover potential therapeutics , ... in the CFTR gene. Each mutation has number of effects ... vitro by Vojo Deretic and colleagues at the University of ... the mechanisms by which one of these changes impacts both ...
... a variety of symptoms, survey found , THURSDAY, Oct. 18 ... reflux, the less typical symptoms of gastroesophageal reflux disease (GERD) ... and chest pain -- can cause people significant sleep problems, ... 701 GERD patients found that sleep impairment was much more ...
... Damon,s Grill, as part of a,three- prong strategy ... trans fats from its menu nationwide. Earlier this ... States and Great Britain, became one of the first,casual ... Damon,s also this year launched its "Lighter Side of ...
... WASHINGTON, Oct. 18 - The nation,s mental,health system ... the U.S. Senate yesterday to provide new resources ... (D-RI) and Gordon H. Smith (R-OR) introduced S.,2182, ... The National Council for Community Behavioral Healthcare, which,championed ...
Cached Medicine News:Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 2Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 3Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 4Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 5Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 6Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 7Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 8Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 9Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 10Health News:Omnicell Reports Strong Q3 Revenue and Profit Growth 11Health News:JCI table of contents: Oct. 18, 2007 2Health News:JCI table of contents: Oct. 18, 2007 3Health News:JCI table of contents: Oct. 18, 2007 4Health News:JCI table of contents: Oct. 18, 2007 5Health News:JCI table of contents: Oct. 18, 2007 6Health News:JCI table of contents: Oct. 18, 2007 7Health News:JCI table of contents: Oct. 18, 2007 8Health News:JCI table of contents: Oct. 18, 2007 9Health News:Damon's Grill Completes Move to Trans Fat-Free Menu 2Health News:New Legislation Seeks to Improve Access to Community Mental Healthcare 2Health News:New Legislation Seeks to Improve Access to Community Mental Healthcare 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: